NPPB and hydrops fetalis: A patient-level meta-analysis of nine clinical trials, which included 2000 patients with chronic heart failure with reduced ejection fraction (HFrEF), showed that NT-proBNP-guided treatment significantly reduced all-cause mortality (hazard ratio [HR], 0.62; 95% CI 0.45–0.86; p = 0.009) compared to conventional HF care [30].